COIOSDeep risk insights through multi-disciplinary research across the globe
brown and white concrete building
Item new Peer-reviewed Added

Real-time glucose monitoring modelled at £5,943 per quality-adjusted life-year

A lifetime model gave £5,943 per QALY for FreeStyle Libre real-time monitoring over finger-prick testing in type 2 diabetes.

The study assessed the cost-effectiveness of FreeStyle Libre real-time continuous glucose monitoring (rtCGM) against self-monitoring of blood glucose (SMBG). Adults had type 2 diabetes above glucose target, on basal insulin plus an SGLT-2 inhibitor and/or GLP-1 agonist. Trial EQ-5D-5L and resource-use data fed the IQVIA CORE Diabetes Model for lifetime projections from the UK NHS perspective. At 32 weeks there was no significant difference in QALYs (-0.015) or costs (£254). Over a lifetime, rtCGM gained 0.730 QALYs for £4,341 more, an ICER of £5,943 per QALY. The lifetime result rests on modelled HbA1c benefits, with at least 4 years of maintained benefit needed for cost-effectiveness.

Why it is interesting: Within the trial, QALYs and costs did not differ significantly, yet the lifetime model gave a low cost per QALY. The result depends on the HbA1c benefit being assumed to last at least 4 years.

Source
Diabetes, Obesity and Metabolism, 15 November 2026
DOI
10.1111/dom.71476
Type
Peer-reviewed article
Design
Within-trial economic evaluation alongside an RCT (EQ-5D-5L and resource use at 16 and 32 weeks) extrapolated to lifetime using the IQVIA CORE Diabetes Model, UK NHS perspective, 3.5% discount
Verdict
New finding
Driver
Value in health
Driver
Obesity, diabetes and GLP-1

Other drivers in Data, models and systems